Abuse Potential of Synthetic Cannabinoids: AM-1248, CB-13, and PB-22
10.4062/biomolther.2020.212
- Author:
Kwang-Hyun HUR
1
;
Shi-Xun MA
;
Bo-Ram LEE
;
Yong-Hyun KO
;
Jee-Yeon SEO
;
Hye Won RYU
;
Hye Jin KIM
;
Seolmin YOON
;
Yong-Sup LEE
;
Seok-Yong LEE
;
Choon-Gon JANG
Author Information
1. Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
- Publication Type:Original Article
- From:Biomolecules & Therapeutics
2021;29(4):384-391
- CountryRepublic of Korea
- Language:English
-
Abstract:
Currently, the expanding recreational use of synthetic cannabinoids (SCBs) threatens public health. SCBs produce psychoactive effects similar to those of tetrahydrocannabinol, the main component of cannabis, and additionally induce unexpected pharmacological side effects. SCBs are falsely advertised as legal and safe, but in reality, SCB abuse has been reported to cause acute intoxication and addictive disorders. However, because of the lack of scientific evidence to elucidate their dangerous pharmacological effects, SCBs are weakly regulated and continue to circulate in illegal drug markets. In the present study, the intravenous self-administration (IVSA) paradigm was used to evaluate the abuse potential of three SCBs (AM-1248, CB-13, and PB-22) in rats. All three SCBs maintained IVSA with a large number of infusions and active lever presses, demonstrating their reinforcing effects.The increase of active lever presses was particularly significant during the early IVSA sessions, indicating the reinforcementenhancing effects of the SCBs (AM-1248 and CB-13). The number of inactive lever presses was significantly higher in the SCB groups (AM-1248 and CB-13) than that in the vehicle group, indicating their impulsive effects. In summary, these results demonstrated that SCBs have distinct pharmacological properties and abuse potential.